Evidence map›Paper›PMID 38276623›Full record

ArticleMolecules (Basel, Switzerland)2024

Encapsulated Rose Bengal Enhances the Photodynamic Treatment of Triple-Negative Breast Cancer Cells.

Mir Muhammad Nasir Uddin, Alina Bekmukhametova, Anu Antony, Shital K Barman, Jessica Houang, Ming J Wu, James M Hook, Laurel George, Richard Wuhrer, Damia Mawad and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Photodynamic Therapy for Toxoplasma gondii Infections Using Rose Bengal.Luminescence : the journal of biological and chemical luminescence · 2026
    Article
  3. Rose Bengal-Chitosan Nanocomposites for Oral Administration.Nanomaterials (Basel, Switzerland) · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Mir Muhammad Nasir UddinSchool of Science, Western Sydney University, Penrith, NSW 2750, Australia.ORCID 0000-0003-3371-6948
Alina BekmukhametovaSchool of Science, Western Sydney University, Penrith, NSW 2750, Australia.ORCID 0000-0003-2542-9412
Anu AntonySchool of Science, Western Sydney University, Penrith, NSW 2750, Australia.ORCID 0000-0001-7962-2387
Shital K BarmanSchool of Science, Western Sydney University, Penrith, NSW 2750, Australia.ORCID 0000-0002-9855-8242
Jessica HouangSchool of Science, Western Sydney University, Penrith, NSW 2750, Australia.ORCID 0000-0003-4387-5918
Ming J WuSchool of Science, Western Sydney University, Penrith, NSW 2750, Australia.ORCID 0000-0003-0577-1907
James M HookSchool of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-1185-7320
Laurel GeorgeAdvanced Materials Characterisation Facility, Western Sydney University, Penrith, NSW 2750, Australia.ORCID 0000-0003-1240-9164
Richard WuhrerAdvanced Materials Characterisation Facility, Western Sydney University, Penrith, NSW 2750, Australia.
Damia MawadSchool of Materials Science and Engineering and Australian Centre for NanoMedicine, University of New South Wales, Kensington, NSW 2052, Australia.ORCID 0000-0002-6965-3232
Daniel TaSchool of Science, Western Sydney University, Penrith, NSW 2750, Australia.
Herleen RupraiSchool of Science, Western Sydney University, Penrith, NSW 2750, Australia.
Antonio LautoSchool of Science, Western Sydney University, Penrith, NSW 2750, Australia.ORCID 0000-0003-4593-5603
Western Sydney University · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among breast cancer subtypes, triple-negative breast cancer stands out as the most aggressive, with patients facing a 40% mortality rate within the initial five years. The limited treatment options and unfavourable prognosis for triple-negative patients necessitate the development of novel therapeutic strategies. Photodynamic therapy (PDT) is an alternative treatment that can effectively target triple-negative neoplastic cells such as MDA-MB-231. In this in vitro study, we conducted a comparative analysis of the PDT killing rate of unbound Rose Bengal (RB) in solution versus RB-encapsulated chitosan nanoparticles to determine the most effective approach for inducing cytotoxicity at low laser powers (90 mW, 50 mW, 25 mW and 10 mW) and RB concentrations (50 µg/mL, 25 µg/mL, 10 µg/mL and 5 µg/mL). Intracellular singlet oxygen production and cell uptake were also determined for both treatment modalities. Dark toxicity was also assessed for normal breast cells. Despite the low laser power and concentration of nanoparticles (10 mW and 5 µg/mL), MDA-MB-231 cells experienced a substantial reduction in viability (8 ± 1%) compared to those treated with RB solution (38 ± 10%). RB nanoparticles demonstrated higher singlet oxygen production and greater uptake by cancer cells than RB solutions. Moreover, RB nanoparticles display strong cytocompatibility with normal breast cells (MCF-10A). The low activation threshold may be a crucial advantage for specifically targeting malignant cells in deep tissues.

Indexed as

PhotochemotherapyTriple Negative Breast NeoplasmsCell Line, TumorHumansPhotosensitizing AgentsRose BengalSinglet OxygenPhotosensitizing AgentsRose BengalSinglet Oxygenlasersreactive oxygen speciesRose Bengaltriple-negative breast cancertumours

Identifiers

PMID38276623
PMCPMC10820979
OpenAlexW4391100481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.